Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010073719) EG5 INHIBITOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/073719 International Application No.: PCT/JP2009/007298
Publication Date: 01.07.2010 International Filing Date: 25.12.2009
IPC:
C07D 209/86 (2006.01) ,A61K 31/403 (2006.01) ,A61K 31/437 (2006.01) ,A61K 31/4745 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/02 (2006.01) ,A61P 37/06 (2006.01) ,A61P 43/00 (2006.01) ,C07D 209/88 (2006.01) ,C07D 471/04 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56
Ring systems containing three or more rings
80
[b, c]- or [b, d]-condensed
82
Carbazoles; Hydrogenated carbazoles
86
with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
4738
ortho- or peri-condensed with heterocyclic ring systems
4745
condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
06
Immunosuppressants, e.g. drugs for graft rejection
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
209
Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
56
Ring systems containing three or more rings
80
[b, c]- or [b, d]-condensed
82
Carbazoles; Hydrogenated carbazoles
88
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
Applicants:
国立大学法人京都大学 Kyoto University [JP/JP]; 京都府京都市左京区吉田本町36番地1 36-1, Yoshida-honmachi, Sakyo-ku, Kyoto-shi, Kyoto 6068501, JP (AllExceptUS)
一般社団法人ファルマIP PHARMA IP GENERAL INCORPORATED ASSOCIATION [JP/JP]; 静岡県三島市文教町一丁目7番25号 7-25, Bunkyo-cho 1-chome, Mishima-shi, Shizuoka 4110033, JP (AllExceptUS)
藤井信孝 FUJII, Nobutaka [JP/JP]; JP (UsOnly)
小川修 OGAWA, Osamu [JP/JP]; JP (UsOnly)
西山博之 NISHIYAMA, Hiroyuki [JP/JP]; JP (UsOnly)
大野浩章 OHNO, Hiroaki [JP/JP]; JP (UsOnly)
大石真也 OISHI, Shinya [JP/JP]; JP (UsOnly)
渡部敏明 WATANABE, Toshiaki [JP/JP]; JP (UsOnly)
竹内智起 TAKEUCHI, Tomoki [JP/JP]; JP (UsOnly)
浅井章良 ASAI, Akira [JP/JP]; JP (UsOnly)
澤田潤一 SAWADA, Junichi [JP/JP]; JP (UsOnly)
Inventors:
藤井信孝 FUJII, Nobutaka; JP
小川修 OGAWA, Osamu; JP
西山博之 NISHIYAMA, Hiroyuki; JP
大野浩章 OHNO, Hiroaki; JP
大石真也 OISHI, Shinya; JP
渡部敏明 WATANABE, Toshiaki; JP
竹内智起 TAKEUCHI, Tomoki; JP
浅井章良 ASAI, Akira; JP
澤田潤一 SAWADA, Junichi; JP
Agent:
廣田雅紀 HIROTA, Masanori; JP
Priority Data:
2008-33196326.12.2008JP
Title (EN) EG5 INHIBITOR
(FR) INHIBITEUR D'EG5
(JA) Eg5阻害剤
Abstract:
(EN) Provided is a novel Eg5 inhibitor which contains, as an active ingredient, a nitrogen-containing heteropolycyclic compound such as a carbazole derivative or a carboline derivative.  The novel Eg5 inhibitor contains, as an active ingredient, a nitrogen-containing heteropolycyclic compound represented by general formula (I) or a pharmacologically acceptable salt thereof.  In general formula (I), the linkages a-b and c-d are each a single or double bond; Q1 to Q4 are each a nitrogen atom or –C(X)=; X and Y1 to Y4 are each a hydrogen atom, an alkyl group, an aralky group, an aryl group, a heterocyclic group, a hydroxyl group, an alkoxy group, a carboxyl group, a halogen atom, or the like; and Z is a hydrogen atom, an alkyl group, or the like.
(FR) Le nouvel inhibiteur d'Eg5 ci-décrit contient, à titre de principe actif, un composé hétéropolycyclique azoté tel qu'un dérivé de carbazole ou un dérivé de carboline. Le nouvel inhibiteur d'Eg5 contient, à titre de principe actif, un composé hétéropolycyclique azoté représenté par la formule générale (I) ou un de ses sels pharmacologiquement acceptables. Dans la formule générale (I), les liaisons a-b et c-d sont chacune une simple ou double liaison ; Q1 à Q4 sont chacun un atome d'azote ou -C(X)= ; X et Y1 à Y4 sont chacun un atome d'hydrogène, un groupe alkyle, un groupe aralkyle, un groupe aryle, un groupe hétérocyclique, un groupe hydroxyle, un groupe alcoxy, un groupe carboxyle, un atome d'halogène, ou un autre groupe similaire ; et Z est un atome d'hydrogène, un groupe alkyle, ou un autre groupe similaire.
(JA) カルバゾール誘導体、カルボリン誘導体等の多環性含窒素複素環化合物を有効成分として含有する新規なEg5阻害剤を提供するものである。下記式(I)で表される多環性含窒素複素環化合物又はその薬理学的に許容される塩を有効成分として含有するEg5阻害剤。(式中、結合a-b及びc-dは、単結合又は二重結合を表し、Q~Qは、窒素原子又は-C(X)=を表し、X及びY~Yは、水素原子、アルキル基、アラルキル基、アリール基、複素環基、ヒドロキシ基、アルコキシ基、カルボキシル基、ハロゲン原子等を表し、Zは、水素原子、アルキル基等を表す)
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)